Last Updated 2 October 2014
The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence of COPD increases as populations age, which is coupled with an increasing diagnosis rate as efforts to promote awareness of the disease continue and the use of spirometry to diagnose COPD becomes more widespread. This expanding COPD patient population has great unmet need because truly disease-modifying pharmacotherapies are lacking; current treatment is dominated by bronchodilators that help alleviate symptoms but do not reverse the progression of COPD. However, polypharmacy is common and therapies that offer incremental improvements over existing treatment modalities will garner use as they alleviate some of the burden associated with pharmacotherapy. Major-market COPD sales will grow substantially over our forecast period owing to the uptake of once-daily, fixed-dose combinations and the increasing drug-treated population.
Questions Answered in This Report:
- Aging demographics and increasing diagnosis rates will lead to an expanded drug-treated population through 2023. What are the emerging opportunities in the expanding COPD drug-treated population? How can marketers attract new COPD patients entering the market?
- New monotherapies from existing classes have begun to enter the COPD market. How has the launch of new long-acting muscarinic antagonists (LAMAs), such as Novartis’s glycopyrronium (Seebri) and Actavis/Almirall/Kyorin’s aclidinium (Tudorza/Eklira), impacted prescribing of Boehringer Ingelheim/Pfizer’s tiotropium (Spiriva)? How will an increasingly competitive market impact the uptake of other recent launches including Novartis’s indacaterol (Arcapta/Onbrez)?
- The only once-daily long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination has begun to launch in the major markets under study. Will GlaxoSmithKline/Theravance’s vilanterol/fluticasone furoate (Breo/Relvar) displace key established agents such as GlaxoSmithKline’s salmeterol/fluticasone propionate (Advair/Seretide/Adoair, generics) and AstraZeneca/Astellas’s formoterol/budesonide (Symbicort, generics)? Will physicians favor inhalers with established molecules or prefer the dosing convenience offered by a once-daily agent with new molecules?
- The COPD market has also seen its newest drug class, the fixed-dose combinations of LABAs and LAMAs, begin to launch in the major markets under study. Will physicians consider twice-daily agents in this class, such as Almirall/Actavis/Kyorin’s formoterol/aclidinium (Duaklir) and AstraZeneca’s formoterol/glycopyrronium, or will they insist on agents with once-daily dosing? To what degree will sales for COPD of Boehringer Ingelheim’s olodaterol/tiotropium cannibalize sales of tiotropium for COPD?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 30 country-specific interviews with thought-leading pulmonologists.
Epidemiology: Prevalence of COPD in patients aged 40 or older; subpopulations by severity (mild, moderate, severe/very severe) and misdiagnosed; growth potential of the COPD population over the 2013-2023 study period.
Emerging therapies: Phase II:  drugs; Phase III:  drugs; preregistration:  drugs; registered:  drug. Coverage of  select preclinical and Phase I products.
Donal Minihan, M.V.B., Ph.D.